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This multi-centre, randomized, double-blind, double-dummy, parallel-group study was designed to investigate the
hypothesis of equivalent ecacy and comparable safety of two inhaled presentations of salmeterol/fluticasone
propionate combination product (SALM/FP) 50/100mg administered twice daily to patients with mild-to-moderate
asthma for 12 weeks. The delivery systems were a 25/50 mg strength hydrofluoroalkane (HFA) metered-dose inhaler
(MDI) and a DiskusTM inhaler (50/100 mg strength). A third group received FP 100mg twice daily via a
chlorofluorocarbon MDI (50 mg strength). A total of 497 patients aged 11–79 years with reversible airways
obstruction who were symptomatic on inhaled corticosteroid (ICS) therapy and had room for improvement in lung
function were randomized to treatment in a double-blind, parallel-group design (SALM/FP MDI: n¼165; SALM/
FP DiskusTM: n¼167; FP MDI: n¼165) for 12 weeks. A total of 383 patients completed the study according to the
protocol.
According to the primary ecacy variable, increase in mean morning PEF over weeks 1–12, the two inhaled
presentations of SALM/FP were clinically equivalent (adjusted mean increases 43 and 46 lmin71; treatment
difference 3 lmin71; 95% confidence interval: 76 to 11 lmin71). Equivalence was also demonstrated by all
secondary ecacy measures. The SALM/FP MDI was significantly superior to the FP MDI for increase in mean
morning PEF (treatment difference 19 lmin71; P50?001) and for all secondary measures except FEV1 and
symptom-free nights. There was no significant difference between the groups with respect to adverse events and
serum cortisol levels.
These results demonstrate that the SALM/FP 25/50 mg HFA MDI (two inhalations twice daily) is clinically
equivalent to the SALM/FP 50/100 mg DiskusTM (one inhalation twice daily). Patients switching to SALM/FP from
other MDI-based asthma treatments may now do so without a change of delivery device.
Key words: salmeterol/fluticasone propionate combination product; metered dose inhaler; DiskusTM; HFA 134a;
equivalence; fluticasone propionate; reversible obstructive airways disease.
RESPIR. MED. (2001) 95, 136–146 # 2001 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2001) 95, 136–146
doi:10.1053/rmed.2000.1008, available online at http://www.idealibrary.com onIntroduction
Although inhaled corticosteroids (ICS) are considered to be
the first-line prophylactic treatment for patients with
persistent asthma (1,2), individuals with more severe diseaseReceived 31 March 2000 and accepted in revised form 2 November
2000.
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0954-6111/01/020136+11 $35?00/0remain symptomatic despite taking these agents. For those
patients who remain symptomatic on ICS therapy, ther-
apeutic options include increasing the dose of ICS or
adding a long-acting b2-agonist (1,2).
Many studies have now been published showing that the
combination of a long-acting b2-agonist with an ICS
provides greater improvement in lung function and
symptom control than at least doubling the dose of ICS
(3–8). Furthermore, it has been shown that this combina-
tion reduces the rate of exacerbations (9,10).
Based on the complementary roles of these two drug
classes and the desire to simplify asthma therapy, the# 2001 HARCOURT PUBLISHERS LTD
SALMETEROL/FLUTICASONE COMBINATION MDI 137long-acting b2-agonist, salmeterol, and the ICS, fluticasone
propionate (FP), have been combined in a single,
multi-dose dry powder DiskusTM inhaler (SeretideTM). A
number of studies in both adults and children have
established that salmeterol and FP have similar ecacy
and tolerability whether they are administered via one
DiskusTM inhaler (the combination product) or via two
separate DiskusTM inhalers (11–14).
More recently, a SALM/FP metered dose inhaler (MDI)
has been developed to provide physicians and patients with
an alternative choice of delivery system. Some patients
prefer to use an MDI, particularly those who require a
spacer. Selection of the most appropriate delivery device for
each patient may facilitate compliance with inhaled asthma
therapy and thereby contribute to greater asthma control.
The MDI is the most commonly prescribed inhalation
device for the delivery of asthma therapy, with approxi-
mately 340 million units used world-wide every year
(15,16). The popularity of the MDI is attributable to its
proven effectiveness and ability to deliver a wide range of
drugs (17). Traditionally, MDIs have been formulated with
a combination of the chlorofluorocarbon (CFC) propel-
lants 11 and 12. However, because of the ozone-depleting
potential of CFCs, the pharmaceutical industry has under-
taken a major research programme to identify alternative
propellants (18). As part of this process, the hydrofluor-
oalkane (HFA) propellant, HFA 134a has been developed.
HFA 134a does not deplete the ozone layer and is approved
by European and other regulatory authorities worldwide
for use as a propellant in MDIs. The SALM/FP MDI has
therefore been formulated with HFA 134a rather than with
CFC propellants.
Three strengths of the SALM/FP MDI have been
developed each containing a constant dose of salmeterol
25 mg combined with FP 50, 125 or 250mg per actuation.
Each dose is given as two actuations. These three strengths
correspond to the three strengths of the SALM/FP
DiskusTM (50/100, 50/250 and 50/500mg) and therefore
provide the same flexibility of steroid dosing allowing a
lower steroid dose to be used.
The aim of this study was to demonstrate equivalent
ecacy and comparable safety of the lowest strength
SALM/FP MDI (25/50 mg; two inhalations twice daily)
and SALM/FP DiskusTM (50/100 mg; one inhalation twice
daily) in adolescents and adults with reversible airways
obstruction. A further objective was to show that the
SALM/FP MDI was more ecacious and as safe as FP
100 mg twice daily administered via a CFC MDI, a well-
established asthma therapy.
Methods
PATIENT POPULATION
Adolescent and adult patients aged 12 years or older were
eligible for study entry if they had a documented clinical
history of reversible airway obstruction, a smoking history
of 510 pack-years and had been using ICS (beclometha-
sone dipropionate, budesonide or flunisolide 400–500mg day71 or FP 200–250 mg day71) for at least 4 weeks
before entering the run-in period. Patients were subse-
quently randomized to study treatment if during the run-in
period they had demonstrated room for improvement in
lung function. This was defined as a mean morning peak
expiratory flow (PEF) over the last 7 days of the run-in
period of 450% and 585% of the PEF measured after
inhalation of salbutamol (400 mg). In addition, they had to
be symptomatic, i.e. have a cumulative total symptom score
(daytime plus night-time) of 8 for the last 7 days of the
run-in period, and be taking salbutamol 800 mg day71.
Forced expiratory volume in 1 sec (FEV1) at randomization
had to be 450% of predicted normal.
Patients were excluded from the study if they had
received a long-acting b2-agonist or oral b2-agonist within
2 weeks of the run-in period, changed their asthma
medication or had a lower respiratory tract infection within
4 weeks of the run-in period or had an acute asthma
exacerbation requiring hospitalization within 12 weeks of
study entry. Other exclusion criteria included prior treat-
ment with oral, depot or parenteral corticosteroids or
combination therapy (containing a b2-agonist and/or ICS).
Written informed consent to participate in the study was
obtained from each patient prior to entry. The study was
approved by the local ethics committee for each centre and
was conducted in accordance with the Declaration of
Helsinki.
STUDY DESIGN
Sixty-nine centres in 10 countries participated in this
randomized, double-blind, double-dummy, parallel-group
study. The study comprised a 2-week run-in period, a 12-
week treatment period and a 2-week follow-up period.
During the run-in period, patients continued to take their
usual ICS therapy, and salbutamol (VentolinTM) was
provided for symptomatic relief. At the end of this period
the patients discontinued their current ICS therapy and
were randomized to one of the following three treatment
groups:
. SALM/FP 25/50 mg two inhalations twice daily via a
pressurized HFA 134a MDI and placebo one
inhalation twice daily via a DiskusTM inhaler.
. SALM/FP 50/100 mg one inhalation twice daily via a
DiskusTM inhaler and placebo two inhalations twice
daily via a pressurized HFA 134a MDI.
. FP 50mg two inhalations twice daily via a pressurized
CFC MDI and placebo one inhalation twice daily via
a DiskusTM inhaler.
The SALM/FP 25/50 mg MDI provided ex-actuator
doses equivalent to salmeterol 21mg and FP 44mg (the FP
MDI also provided FP 44 mg ex-actuator).
All other regular asthma therapy (including anti-choli-
nergics and theophylline) was continued provided that the
dose remained constant. Patients were allowed to use a
VolumaticTM spacer with the active or placebo MDI,
provided it was used for the duration of the study.
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Patients measured their daily morning and evening PEF,
using a mini-Wright peak flow meter, before taking the
study medication or rescue VentolinTM. The highest of
three measurements was recorded on a daily record card
throughout the study, together with the daytime and night-
time use of as-needed salbutamol. Patients also kept a daily
record card of their daytime symptom score using a six-
point scale (0¼no symptoms during the day; 5¼symptoms
so severe that the patient was unable to go to work or
school or perform normal daily activities) and night-time
symptom score using a 5-point scale (0¼no symptoms
during the night; 4¼symptoms so severe that the patient
could not sleep at all).
Clinic FEV1 (highest of three measurements) was
measured at the beginning and end of the run-in period
and at weeks 2, 4, 8 and 12 of the treatment period. Patients
were asked to withhold their rescue medication for at least
6 h before each clinic visit and to withhold their study
medication on the morning of each visit. Whenever possible
FEV1 measurements were made at the same time of day at
each clinic visit.
ADVERSE EVENTS
All adverse events occurring at any time during the study
were recorded, irrespective of their likely causality. A
serious adverse event was described as any event which was
fatal, life-threatening, disabling or incapacitating, or which
required or prolonged hospitalization.
Oropharyngeal examinations were performed before
randomization and at weeks 4, 8 and 12 of the treatment
period. If there was clinical evidence of Candida a swab was
taken.
Blood samples were collected between 08.00 hours and
10.00 hours, at the end of the run-in and treatment periods,
for routine biochemical and haematological analyses and
measurement of morning serum cortisol concentrations. A
physical examination was also performed and vital signs
(blood pressure and heart rate) were monitored.
STATISTICAL ANALYSIS
The primary ecacy variable was mean morning PEF over
weeks 1–12. This was analysed using both the intent-to-
treat (ITT) and per protocol populations (the ITT
population with no major protocol violations). Based on
a requirement for 90% power, a sample size of 165 patients
per treatment group was required to demonstrate equiva-
lence between the SALM/FP MDI and DiskusTM groups.
The treatment groups were prospectively defined as
equivalent if the 95% confidence intervals (CIs) for the
treatment difference were between +15 lmin71 for both
the ITT and per protocol populations (19). Effects due to
centre, sex, age, baseline lung function, spacer usage and
previous ICS therapy were also tested for the primary
ecacy variable.
The secondary ecacy measures included evening PEF,
daytime and night-time symptom scores, use of as-requiredsalbutamol and clinic FEV1. Both the ITT and per protocol
populations were used to analyse mean evening PEF and
clinic FEV1. All other secondary analyses were conducted
using the ITT population. Differences between the SALM/
FP MDI and FP MDI groups were analysed; however, in
order to reduce the effects of multiple testing there was no
statistical comparison between the SALM/FP DiskusTM
and FP MDI groups.
Change in PEF, PEF per cent predicted, circadian
variation in PEF and clinic FEV1 were analysed using
analysis of covariance (ANCOVA), allowing for effects due
to centre, sex, age and baseline. Symptom scores, percen-
tage of symptom-free days and nights, and days and nights
with no rescue salbutamol were analysed using the Mann–
Whitney Wilcoxon sum test. Withdrawals were analysed
using Fisher’s exact test.
Serum cortisol data were logarithmically transformed
and analysed using ANCOVA with covariates of age, sex,
centre and log baseline. Least square means for the
treatments were transformed back to the original scale
and presented as geometric means.
Results
A total of 724 patients entered the run-in period, of whom
497 were subsequently randomized to treatment: 165
received the SALM/FP MDI, 167 the SALM/FP DiskusTM
and 165 the FP MDI. After randomization, 67 patients
were withdrawn, 20 (12%) in the SALM/FP MDI group,
22 (13%) in the SALM/FP DiskusTM group and 25 (15%)
in the FP MDI group. Reasons for withdrawal included
adverse events (seven, eight and 11 patients in the three
groups, respectively), protocol violations (four, two and
three patients, respectively), lost to follow-up (one, three
and two patients, respectively), failure to fulfil the entry
criteria (0, three, and three patients, respectively), lack of
ecacy (one, two and 0 patients, respectively), non-
compliance (two, one, and 0 patients, respectively) and
other (five, three and six patients, respectively). The most
common adverse event leading to withdrawal was a
worsening of asthma symptoms.
The per protocol population comprised 383 patients
(SALM/FP MDI: n¼128; SALM/FP DiskusTM: n¼131; FP
MDI: n¼124). A total of 114 patients were excluded from
the per protocol population; the most common reasons for
exclusion were: PEF outside the stated range at baseline
(450% and585% of PEF measured after salbutamol use)
(n¼52) and baseline symptom score 7 (n¼30).
With the exception of morning PEF at baseline, the three
treatment groups were well matched for demographic and
baseline characteristics (Table 1). A similar number of
patients used a spacer device throughout the study (24, 22
and 26 patients, respectively, in the SALM/FP MDI,
SALM/FP DiskusTM and FP MDI groups).
LUNG FUNCTION
During the 12-week treatment period, morning PEF
increased by 42, 43 and 22 lmin71 in the SALM/FP
TABLE 1. Summary of demographic and baseline characteristics (intent-to-treat population)
SALM/FP 50/100 mg
HFA MDI
SALM/FP 50/100 mg
DiskusTM
FP 100 mg
CFC MDI
No. of patients 165 167 165
Male (n) 73 (44%) 79 (47%) 67 (41%)
Female (n) 92 (56%) 88 (53%) 98 (59%)
Mean age (years; range)* 40?7 (11–78) 38?6 (11–79) 39?5 (12–76)
History of atopy (n) 90 (55%) 102 (61%) 91 (55%)
Duration of airways disease (n)
0 to 51 year 10 (6%) 12 (7%) 11 (7%)
1 to 55 years 49 (30%) 35 (21%) 37 (22%)
5 to 510 years 29 (18%) 34 (20%) 33 (20%)
10 years 77 (46%) 86 (52%) 84 (51%)
Currently using a spacer (n) 24 (15%){ 22 (13%) 26 (16%)
Current smoker (n) 22 (13%) 15 (9%) 18 (11%)
Ex-smoker (n) 25 (17%) 39 (25%) 32 (21%)
Baseline lung function (mean):
am PEF (lmin71) 353 373 354
PEF % predicted 80 81 80
FEV1 % predicted 75 76 76
Mean reversibility in FEV1 (%) 16?9 16?8 18?2
Inhaled corticosteroid therapy prior
to randomization (n)
Beclomethasone dipropionate 61 (37%) 65 (39%) 66 (40%)
Budesonide 59 (36%) 51 (31%) 44 (27%)
Fluticasone propionate 42 (25%) 50 (30%) 53 (32%)
Flunisolide 2 (1%) 1 (51%) 1 (51%)
*Two male patients (one in the SALM/FP HFA MDI and one in the SALM/FP DiskusTM group) were aged 11 years. These
two patients were included in the intent-to-treat but not in the per protocol population.
{n¼164; data missing for one patient.
CFC: chlorofluorocarbon; FEV1: forced expiratory volume in 1 sec; FP: fluticasone propionate; HFA: hydrofluoroalkane;
MDI: metered dose inhaler; am PEF: morning peak expiratory flow; SALM/FP: salmeterol/FP combination product.
FIG. 1. Change in morning peak expiratory flow (PEF)
from baseline during twice daily treatment with
salmeterol/fluticasone propionate (FP) 50/100 mg
combination product (SALM/FP) administered via a
hydrofluoroalkane (HFA) metered dose inhaler (MDI) or
a DiskusTM inhaler, or FP 100 mg via a
chlorofluorocarbon (CFC) MDI for 12 weeks. Data are
presented as mean (+SE) for the intent-to-treat
population. —: SALM/FP 50/100 mg MDI; – – –: SALM/
FP 50/100 mg DiskusTM; - - -: FP 100 mg MDI.
SALMETEROL/FLUTICASONE COMBINATION MDI 139MDI, SALM/FP DiskusTM and FP MDI groups, respec-
tively (Fig. 1). The SALM/FP MDI was clinically
equivalent to the SALM/FP DiskusTM for the primary
ecacy variable, improvement in mean morning PEF over
weeks 1–12 in both the ITT and per protocol populations.
The adjusted mean increase from baseline in the two groups
was 43 and 46 lmin71, respectively, in the ITT population
(treatment difference 3 lmin71; 95% CI: 76–11 lmin71)
(Table 2). In the per protocol population, the correspond-
ing difference was 2 lmin71 (95% CI: 77–12).
The SALM/FP MDI was significantly more effective
than the FP MDI with respect to adjusted mean change in
morning PEF from baseline (adjusted mean treatment
difference weeks 1–12: 719 lmin71; 95% CI: 728, 711;
P50?001) and this difference was evident after only 1 week
of treatment (Table 2). In order to reduce the effects of
multiple testing there was no statistical comparison between
the SALM/FP DiskusTM and FP MDI. However, given the
equivalence of the SALM/FP DiskusTM and MDI for-
mulation it might reasonably be expected that such a
comparison would have shown similar results to the
comparison of the SALM/FP and FP MDIs.
TABLE 2. Morning peak expiratory flow (PEF) (intent-to-treat population)
Week 1 Weeks 1–4 Weeks 5–8 Weeks 9–12 Weeks 1–12
SALM/FP 50/100mg HFA MDI
n 162 163 153 149 163
Adjusted mean change
from baseline*
32 38 45 49 43
SALM/FP 50/100mg DiskusTM
n 167 167 152 148 167
Adjusted mean change
from baseline*
38 43 49 51 46
Mean difference{ (95% CI) 6 (71, 13) 5 (72, 13) 4 (76, 14) 3 (78, 13) 3 (76, 11)
P-value 0?095 0?182 0?406 0?624 0?500
FP 100mg CFC MDI
n 162 162 148 142 162
Adjusted mean change
from baseline*
15 21 28 30 24
Mean difference{ (95% CI) 717 (724, 710) 717 (725, 79) 717 (727, 77) 719 (729, 78) 719 (728, 711)
P-value 50?001 50?001 50?001 50?001 50?001
*Adjusted for baseline, age, sex and centre.
{Comparator minus SALM/FP MDI.
CFC: chlorofluorocarbon; CI: confidence interval; FP: fluticasone propionate; HFA: hydrofluoroalkane; MDI: metered dose
inhaler; SALM/FP: salmeterol/FP combination product.
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regardless of which ICS had been used prior to study
entry. However, an interaction between treatment and
spacer use was seen in the per protocol population (total of
59 patients used a spacer): the effect of treatment on mean
morning PEF was apparently smaller in patients using the
SALM/FP DiskusTM than in those on the SALM/FP MDI.
As the former patients were using a spacer only for their
placebo medication (via MDI), this is likely to be a chance
occurrence.
Mean morning PEF, as a percentage of the maximum
PEF recorded after salbutamol use, was 79% in all three
groups at baseline and 89%, 88% and 84% in the SALM/
FP MDI, SALM/FP DiskusTM and FP MDI groups,
respectively, during weeks 1–12, indicating that patients
had not attained maximum PEF.
Mean evening PEF, and percent predicted mean morning
and evening PEF improved from baseline in all three
treatment groups, with the greatest improvement in the
SALM/FP MDI and DiskusTM groups (Table 3). The
SALM/FP MDI produced significantly greater improve-
ments in these secondary ecacy variables than the FP
MDI during weeks 1–12 (Table 3). Similarly, a decrease in
circadian variation in PEF was reported in all three
treatment groups, indicating improved asthma control
(Table 3).
CLINIC FEV1
Clinic FEV1 improved in all three groups during the
treatment period (Table 4). Increases from baseline of 17%,15% and 15% were reported at week 12 in the SALM/FP
MDI, SALM/FP DiskusTM and FP MDI groups, respec-
tively. Differences between the SALM/FP MDI and the
other two groups were not statistically significant.
SYMPTOM SCORES
The number of symptom-free days and nights increased in
all three treatment groups (Table 5). The median propor-
tions of symptom-free days and nights over weeks 1–12
were similar in the SALM/FP MDI and DiskusTM groups
(respectively: 55% and 52% for days and 71% and 78% for
nights; Table 5). In comparison with the FP MDI group,
the SALM/FP MDI group reported significantly more
symptom-free days (weeks 1–12: 55 vs. 25%; 95% CI:719,
72; P¼0?001) (Fig. 2), and more symptom-free nights (71
vs. 53%; 95% CI: 714, 0; P¼0?063) (Table 5).
USE OF RESCUE MEDICATION
There were similar increases in the number of salbutamol-
free days and nights in the SALM/FP MDI and DiskusTM
groups (Table 5). During weeks 1–12, the respective median
proportions of salbutamol-free days in these groups were
73% and 75%, and 90% and 93% for nights. Significantly
more salbutamol-free days and nights were reported in the
SALM/FP MDI group than in the FP MDI group for all
except one assessment period (salbutamol-free nights
during weeks 5–8) (Table 5).
TABLE 3. Other diary card parameters (intent-to-treat population)
Baseline
Adjusted mean change
from baseline
weeks 1–12*
Mean difference{
(95% CI) P-value
Mean am PEF (% pred)
SALM/FP 50/100mg HFA MDI 80 10
SALM/FP 50/100mg DiskusTM 81 10 0 (72, 2) 0?928
FP 100 mg CFC MDI 80 5 75 (77, 73) 50?001
Mean pm PEF (lmin71)
SALM/FP 50/100mg HFA MDI 364 38
SALM/FP 50/100mg DiskusTM 389 35 73 (711, 5) 0?472
FP 100 mg CFC MDI 367 18 720 (728, 712) 50?001
Mean pm PEF (% pred)
SALM/FP 50/100mg HFA MDI 83 9
SALM/FP 50/100mg DiskusTM 84 8 71 (73, 1) 0?294
FP 100 mg CFC MDI 83 4 75 (77, 73) 50?001
PEF circadian variation{ (%)
SALM/FP 50/100mg HFA MDI 9 73
SALM/FP 50/100mg DiskusTM 9 73 71 (71, 0) 0?198
FP 100 mg CFC MDI 9 72 1 (0, 1) 0?221
*Adjusted for baseline, age, sex and centre.
{Comparator minus SALM/FP MDI.
{Circadian variation¼absolute value (pm PEF7am PEF)6100%/mean(am PEF, pm PEF).
am PEF: morning PEF; CFC: chlorofluorocarbon; CI: confidence interval; FP: fluticasone propionate; HFA:
hydrofluoroalkane; MDI: metered dose inhaler; PEF: peak expiratory flow; pm PEF: evening PEF; SALM/FP: salmeterol/
FP combination product.
TABLE 4. Clinic forced expiratory volume in 1 sec (FEV1)
Baseline
Adjusted mean
change from baseline
(week 12)*
Mean difference*
(95% CI) P-value
Clinic FEV1 (l)
SALM/FP 50/100mg HFA MDI 2?37 0?38
SALM/FP 50/100mg DiskusTM 2?47 0?33 70?05 (70?16, 0?07) 0?404
FP 100 mg CFC MDI 2?44 0?32 70?06 (70?18, 0?05) 0?282
FEV1 (% pred)
SALM/FP 50/100mg HFA MDI 76 12?2
SALM/FP 50/100mg DiskusTM 75 9?5 72?7 (76?2, 0?8) 0?135
FP 100 mg CFC MDI 76 9?4 72?8 (76?3, 0?7) 0?122
*Comparator minus SALM/FP MDI.
CFC: chlorofluorocarbon; CI: confidence interval; FP: fluticasone propionate; HFA: hydrofluoroalkane; MDI: metered dose
inhaler; SALM/FP: salmeterol/FP combination product.
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The overall incidence of adverse events was similar in the
three treatment groups. Eighty-two patients (50%) in the
SALM/FP MDI group, 95 (57%) in the SALM/FP
DiskusTM group and 90 (55%) in the FP MDI groupexperienced at least one adverse event during treatment.
The most common adverse events (reported by 4% of
patients in any one group) are summarized in Table 6.
Upper respiratory tract infections were the most frequently
reported adverse events, occurring in 19 (12%), 29 (17%)
and 21 patients (13%) in the SALM/FP MDI, SALM/FP
TABLE 5. Symptom-free and salbutamol-free days and nights
Baseline Week 1 Weeks 1–4 Weeks 5–8 Weeks 9–12 Weeks 1–12
Symptom-free days (%)
SALM/FP 50/100mg HFA MDI
Median 0 17 39 64 68 55
SALM/FP 50/100mg DiskusTM
Median
Median difference* (95% CI)
P-value
0 29
0 (0, 0)
0?405
44
0 (74, 6)
0?831
59
0 (75, 4)
0?875
62
0 (75, 1)
0?582
52
0 (75, 5)
0?978
FP 100 mg CFC MDI
Median
Median difference* (95% CI)
P-value
0 0
0 (710, 0)
0?022
15
77 (718, 0)
0?002
27
710 (721, 0)
0?001
30
77 (721, 0)
0?006
25
710 (719, 72)
0?001
Median symptom-free nights (%)
SALM/FP 50/100mg HFA MDI
Median 29 57 68 77 79 71
SALM/FP 50/100mg DiskusTM
Median
Median difference* (95% CI)
P-value
29 71
0 (0, 0)
0?618
74
1 (0, 10)
0?283
82
0 (0, 7)
0?336
89
0 (0, 6)
0?266
78
2 (71, 9)
0?273
FP 100 mg CFC MDI
Median
Median difference* (95% CI)
P-value
20 43
0 (714, 0)
0?100
43
77 (715, 0)
0?051
61
0 (710, 0)
0?191
67
71 (711, 0)
0?107
53
75 (714, 0)
0?063
Median salbutamol-free days (%)
SALM/FP 50/100mg HFA MDI
Median 14 57 64 82 86 73
SALM/FP 50/100mg DiskusTM
Median
Median difference* (95% CI)
P-value
0 57
0
0?541
58
0
0?784
86
0
0?693
82
0
0?658
75
0
0?964
FP 100 mg CFC MDI
Median
Median difference* (95% CI)
P-value
0 29
75
0?008
46
711
0?003
63
78
0?002
68
77
0?004
58
79
0?003
Median salbutamol-free nights (%)
SALM/FP 50/100mg HFA MDI
Median 57 100 89 93 96 90
SALM/FP 50/100mg DiskusTM
Median
Median difference* (95% CI)
P-value
57 86
0
0?707
91
0
0?949
96
0
0?325
96
0
0?951
93
0
0?640
FP 100 mg CFC MDI
Median
Median difference* (95% CI)
P-value
57 71
0
0?009
78
74
0?011
82
0
0?093
85
0
0?012
80
72
0?033
*Comparator minus SALM/FP MDI.
CFC: chlorofluorocarbon; CI: confidence interval; FP: fluticasone propionate; HFA: hydrofluoroalkane; MDI: metered dose
inhaler; SALM/FP: salmeterol/FP combination product.
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asthma exacerbations during the study was similar and low
in the three groups [four–five reports per group (2–3%)].
Adverse events were assessed by the investigators as
drug-related in 13 (8%), 18 (11%) and 14 patients (8%) in
the SALM/FP MDI, SALM/FP DiskusTM and FP MDIgroups, respectively. Candidiasis of the mouth and/or
throat was the only drug-related adverse event reported
by more than 1% of patients in any treatment group [one
(51%), four (2%) and one (51%) patient, respectively].
During treatment, serious adverse events were reported by
three patients (2%) in each group. These included asthma
FIG. 2. Median proportion of symptom-free days during
twice daily treatment with salmeterol/fluticasone
propionate (FP) 50/100 mg combination product (SALM/
FP) administered via a hydrofluoroalkane metered dose
inhaler (MDI) or a DiskusTM inhaler, or FP 100mg via a
chlorofluorocarbon MDI for 12 weeks. Differences
compared with SALM/FP MDI: **P50.01;
***P50.001; ns: not significant. &: SALM/FP MDI; &:
SALM/FP DiskusTM; : FP MDI.
TABLE 7. Serum cortisol levels for samples collected between 08
Serum cortisol (nmol l71)
SALM/FP 50/100mg
HFA MDI
Baseline
Geometric mean (CV)
n
335.1 (55.9)
114
After 12 weeks
Geometric mean (CV)
n
352.5 (44.0)
110
Change from baseline
Mean (SD)
Geometric mean ratio
n
13.8 (137.0)
1.08
87
CFC: chlorofluorocarbon; CV: coecient of variation; FP: fluti
dose inhaler; SALM/FP: salmeterol/FP combination product; S
TABLE 6. Incidence (%) of most common adverse events during
Adverse event
SALM/FP 50/100
HFA MDI
Upper respiratory tract infection 12
Headache 8
Viral respiratory infection 4
Rhinitis 51
Pharyngitis/throat infection 3
Sinusitis 2
CFC: chlorofluorocarbon; FP: fluticasone propionate; HFA:
salmeterol/FP combination product.
SALMETEROL/FLUTICASONE COMBINATION MDI 143exacerbations (n¼5), breast neoplasia (n¼1) and events
associated with the gastrointestinal system (n¼2) and ear,
nose and throat (n¼1). The only serious adverse events
considered by the investigator to be drug-related were
asthma exacerbations in two patients (one each in the
SALM/FP MDI and DiskusTM groups).
SERUM CORTISOL
After 12 weeks of treatment there was a small increase in
mean morning serum cortisol levels from baseline in all
three groups (geometric mean ratios 1?08 to 1?21) (Table 7).
Analysis of the adjusted geometric mean morning serum
cortisol levels at week 12 showed no significant difference
between the SALM/FP MDI group and either the SALM/
FP DiskusTM group (ratio¼1?04; 95% CI: 0?93, 1?16;
P¼0?495) or the FP MDI group (ratio¼1?08; 95% CI: 0?97,
1?20; P¼0?155). Only eight patients (evenly distributed.00 and 10.00 hours
SALM/FP 50/100 mg
DiskusTM
FP 100 mg
CFC MDI
349.7 (47.9)
112
328.0 (49.8)
118
373.1 (40.7)
108
366.4 (50.6)
107
20.5 (145.9)
1.09
86
62.7 (172.1)
1.21
81
casone propionate; HFA: hydrofluoroalkane; MDI: metered
D: standard deviation.
treatment (reported by 4% of patients in any one group)
mg SALM/FP 50/100 mg
DiskusTM
FP 100mg
CFC MDI
17 13
8 6
4 5
5 3
2 4
4 3
hydrofluoroalkane; MDI: metered dose inhaler; SALM/FP:
144 E. D. BATEMAN ET AL.between the groups) recorded serum cortisol values below
the reference range at the end of treatment.
Discussion
This study demonstrates that the SALM/FP MDI and the
SALM/FP DiskusTM inhaler are clinically equivalent when
administered at a dose of 50/100mg twice daily to patients
with mild to moderate asthma who were symptomatic on
ICS alone. The SALM/FP MDI was equivalent to the
SALM/FP DiskusTM in terms of the primary ecacy
variable, improvement in morning PEF from baseline
during weeks 1–12. The two treatments were also compar-
able with respect to the secondary ecacy measures,
including daily symptom scores, evening PEF and use of
rescue salbutamol. These results are consistent with those
from a similar clinical study at higher doses of SALM/FP
(50/500 mg twice daily), in which HFA 134a MDI and
DiskusTM presentations had equivalent ecacy (20).
To ensure that true clinical equivalence of the two
SALM/FP delivery systems could be established, strict
patient entry criteria were set to avoid making comparisons
at the plateau of the dose–response curve. This was
achieved by randomizing only those patients who showed
room for improvement in lung function during the run-in
period (defined as a mean morning PEF of 450% and
585% of the PEF measured after inhalation of salbuta-
mol) (21). Indeed, patients still had scope for improvement
at the end of the study; the mean morning PEF achieved
during weeks 1–12 was 84–89% in the three groups (values
expressed as a percentage of the maximum achievable PEF
recorded in response to salbutamol). These findings suggest
that some patients could have achieved better asthma
control if they had been treated with a higher dose of
SALM/FP; however, the patient selection criteria allowed
differences to be detected between the SALM/FP MDI and
FP MDI groups, so confirming that the study design was
appropriate.
Two study populations were assessed for ecacy, the
ITT and per protocol populations. The results for the two
populations were similar, indicating that the exclusion of a
large number of patients from the per protocol population
did not alter the conclusions of the study. Furthermore, a
sucient number of patients was enrolled in the ITT
population (n¼497) to ensure adequate power for the
primary ecacy analysis. The patients in each treatment
group were well matched for baseline and demographic
characteristics, except for a difference in morning PEF at
baseline in the SALM/FP MDI and DiskusTM groups; this
was taken into account by presentation of the results as
adjusted means.
The SALM/FP MDI was superior to the FP MDI for the
primary ecacy variable, change in mean morning PEF
from baseline, and for many of the secondary ecacy
measures. The overall superior ecacy of SALM/FP
confirms the findings of earlier studies comparing combina-
tion or concurrent therapy with these two drugs with FP
alone (14,22). There was no significant difference between
the SALM/FP and FP MDIs with respect to the percentageof symptom-free nights; however, this may have been
because the overall incidence of night-time symptoms was
too low to enable a difference to be detected at this level of
power (median symptom score of 0 over weeks 1–12 in all
groups).
The SALM/FP MDI and DiskusTM and the FP MDI
were equally well tolerated. The incidence and pattern of
adverse events were as expected for a clinical trial of this
nature in a population of asthmatic patients. The incidence
of oral candidiasis was low in all three treatment groups.
There was no evidence of adrenal suppression in any
treatment group. Effects on hypothalamic–pituitary adrenal
(HPA) axis function were similar for the SALM/FP MDI
and DiskusTM at equivalent FP doses, and HPA function
tended to improve during the study compared with baseline
in all three groups. Although morning serum cortisol is not
the most sensitive measure of HPA axis function, it is a
practical means of assessment in large multi-centre studies
and can be used to detect clinically significant differences
between treatments if they exist.
There has been concern that regular treatment with
inhaled b2-agonists may mask any deterioration in inflam-
mation and increase the rate and severity of asthma
exacerbations (23). However, there is a significant body of
clinical evidence to suggest that such deterioration in
asthma control does not occur. Exacerbation rates were
reduced when a long-acting b2-agonist was added to ICS
therapy for 12 months in the FACET study (9,24); a recent
meta-analysis of other studies reported similar findings (10).
The FACET study also demonstrated that treatment with a
long-acting b2-agonist had no effect on the severity of
exacerbations (24). In addition, retrospective analysis has
shown that a long-acting b2-agonist does not alter the
physicians’ or patients’ recognition of signs and symptoms
of deteriorating asthma (25).
Although the duration of this study was relatively short
(12 weeks), the incidence and severity of asthma exacerba-
tions was low and similar in all three treatment groups,
further supporting this finding.
The SALM/FP MDI is the first asthma therapy in which
two complementary classes of drug, an ICS and a long-
acting b2-agonist, are combined in a single MDI formulated
with a non-CFC propellant. The DiskusTM dry powder
inhaler provides consistent dose delivery (26,27), has low
resistance compared with other dry powder inhalers (28,29)
and is easy to use and well accepted by physicians and
patients (30,31). Giving patients and physicians a means
of delivering SALM/FP via a single inhaler, and offering
a choice of two devices for such delivery, may each have
a beneficial effect on patient compliance with asthma
therapy.
In conclusion, the ecacy and safety of SALM/FP 50/
100mg twice daily is comparable whether administered via
the HFA 134a MDI or DiskusTM, giving patients a choice
of delivery systems while retaining the simplicity of
prescribing. This should also help patients who are switched
to SALM/FP therapy from other asthma treatments; those
who remain uncontrolled on ICS or b2-agonists alone can
continue to use the MDI rather than learning how to use
a new device, and those who are taking a long-acting
SALMETEROL/FLUTICASONE COMBINATION MDI 145b2-agonist and an inhaled corticosteroid concurrently via
separate MDIs will need only a single inhaler.
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